Assyro AI

FDA Orange Book · active-ingredient family

Uridine triacetate

Uridine triacetate is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:VISTOGARD · NDA 208159

2

Brand (NDA)

0

Generics (ANDA)

1

Listed patents

0

Exclusivity periods

Brand (NDA) products · granule

ProductApplicantApplicationTEApproved
VISTOGARDRLDBTG INTLNDA 208159—Dec 11, 2015
XURIDENRLDBTG INTLNDA 208169—Sep 04, 2015

Listed patents (1)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7776838Aug 17, 2027in 1 yr 2 mo
U-1791

Uridine triacetate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo